AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 0.89 |
Market Cap | 73.95M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.7 |
PE Ratio (ttm) | -0.53 |
Forward PE | n/a |
Analyst | Buy |
Ask | 0.91 |
Volume | 80,940 |
Avg. Volume (20D) | 597,731 |
Open | 0.92 |
Previous Close | 0.91 |
Day's Range | 0.89 - 0.94 |
52-Week Range | 0.81 - 3.62 |
Beta | undefined |
About ACET
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes AD...
Analyst Forecast
According to 4 analyst ratings, the average rating for ACET stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 457.17% from the latest price.
2 weeks ago · businesswire.com
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
4 weeks ago · businesswire.com
Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical OfficerREDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
2 months ago · businesswire.com
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...